NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
Clinical Trials
27 trialsNCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT05346835 2026-02-13
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Janssen Scientific Affairs, LLC
Available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT05161598 2025-12-16
Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
Janssen Research & Development, LLC
No longer available
NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT04771078 2025-12-12
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Celgene
Available
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT04452994 2025-06-13
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT05238311 2025-02-04
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pfizer
No longer available
NCT03763370 2024-10-15
Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
GlaxoSmithKline
Available
NCT05462639 2024-08-09
MAGNETISMM17
Pfizer
No longer available
NCT02856438 2023-12-19
Early Patient Access Treatment Use Protocol CA204-220
Bristol-Myers Squibb
No longer available
NCT02368301 2023-11-30
Expanded Access Treatment Protocol CA204-143
Bristol-Myers Squibb
No longer available
NCT03126617 2021-11-29
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Bristol-Myers Squibb
No longer available
NCT04453397 2021-09-23
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
TeneoOne Inc.
No longer available
NCT02568943 2020-04-08
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Novartis
No longer available
NCT01632826 2019-11-12
PEXIUS
Celgene
Approved for marketing
NCT02477891 2019-01-15
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT03723096 2018-12-20
Expanded Access for CC-4047
Celgene
No longer available
NCT01410500 2017-05-02
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Amgen
Approved for marketing
NCT02204553 2016-01-05
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Novartis
No longer available
NCT00799539 2015-12-02
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
Janssen-Ortho Inc., Canada
No longer available
NCT00720603 2015-03-24
EAP
Sanofi
No longer available
NCT00063791 2007-02-14
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Millennium Pharmaceuticals, Inc.
No longer available